You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyproheptadine
Accession NumberDB00434  (APRD00033)
TypeSmall Molecule
GroupsApproved
DescriptionA serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [PubChem]
Structure
Thumb
Synonyms
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
Axoprol
Ciproheptadina
Cyproheptadin
Cyproheptadine
Cyproheptadinum
Dihexazin
Glutodina
External Identifiers
  • Fl 5967
  • HSp 1229
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyproheptadinesyrup2 mg/5mLoralPharmaceutical Associates, Inc.2013-07-29Not applicableUs
Cyproheptadinesyrup2 mg/5mLoralPharmaceutical Associates, Inc.2013-07-29Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralREMEDYREPACK INC.2011-09-22Not applicableUs
Cyproheptadine Hydrochloridesyrup2 mg/5mLoralRising Pharmaceuticals, Inc.2006-07-10Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralTeva Pharmaceuticals USA Inc2009-01-23Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralREMEDYREPACK INC.2012-08-16Not applicableUs
Cyproheptadine Hydrochloridesyrup2 mg/5mLoralActavis Mid Atlantic LLC2009-07-31Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralCardinal Health2010-06-15Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralREMEDYREPACK INC.2011-09-20Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralCarilion Materials Management2010-06-15Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralREMEDYREPACK INC.2013-12-312016-04-05Us
Cyproheptadine Hydrochloridetablet4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-08Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralbryant ranch prepack2009-01-23Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralIngenus Pharmaceuticals Llc2015-09-23Not applicableUs
Cyproheptadine Hydrochloridesyrup2 mg/5mLoralCarilion Materials Management2006-07-10Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralPhysicians Total Care, Inc.2003-05-21Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralMirror Pharmaceuticals LLC2015-09-23Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralAv Kare, Inc.2010-06-15Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralCore Pharma, Llc2015-07-29Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralBreckenridge Pharmaceutical, Inc.2013-10-21Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralC.O. Truxton, Inc.2010-06-15Not applicableUs
Cyproheptadine Hydrochloridesyrup2 mg/5mLoralPhysicians Total Care, Inc.2009-07-31Not applicableUs
Cyproheptadine Hydrochloridetablet4 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyproheptadine 4mg Tabletstablet4 mgoralJamp Pharma Corporation2010-05-03Not applicableCanada
Euro-cyproheptadine 2mg/5mlsyrup2 mgoralSandoz Canada Incorporated2003-05-27Not applicableCanada
Euro-cyproheptadine 4mg/tablettablet4 mgoralSandoz Canada Incorporated2006-06-05Not applicableCanada
Jamp Cyproheptadine Syrupsyrup0.4 mgoralJamp Pharma CorporationNot applicableNot applicableCanada
Periactin Syr 2mg/5mlsyrup2 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1961-12-312002-07-29Canada
Periactin Tab 4mgtablet4 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1961-12-312002-07-29Canada
PMS-cyproheptadine HCl Tab 4mgtablet4 mgoralPharmascience Inc1996-10-16Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
ApeplusRadicura
ApitupUniversal
BioheptBiofarm
CiplactinCipla
CipractineTeriak
CiproheptadinaArena
CiprovitNot Available
CiptadineIBN
CyheptineGreater Pharma
CyllerminCCPC
PeriactinMerck
PeriactineTeofarma
PeriatinApex
ReactinOrion
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cyproheptadine Hydrochloride
Thumb
  • InChI Key: ZPMVNZLARAEGHB-UHFFFAOYSA-N
  • Monoisotopic Mass: 323.144077416
  • Average Mass: 323.859
DBSALT000625
Categories
UNII2YHB6175DO
CAS number129-03-3
WeightAverage: 287.3981
Monoisotopic: 287.167399677
Chemical FormulaC21H21N
InChI KeyInChIKey=JJCFRYNCJDLXIK-UHFFFAOYSA-N
InChI
InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
IUPAC Name
1-methyl-4-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}piperidine
SMILES
CN1CCC(CC1)=C1C2=CC=CC=C2C=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine.
PharmacodynamicsCyproheptadine is a piperidine antihistamine. Unlike other antihistamines, this drug also antagonizes serotonin receptors. This action makes Cyproheptadine useful in conditions such as vascular headache and anorexia. Cyproheptadine does not prevent the release of histamine but rather competes with free histamine for binding at HA-receptor sites. Cyproheptadine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. Most antihistamines possess significant anticholinergic properties, but Cyproheptadine exerts only weak anticholinergic actions. Blockade of central muscarinic receptors appears to account for Cyproheptadine's antiemetic effects, although the exact mechanism is unknown. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite. Cyproheptadine also has been used to counter vascular headaches, which many believe are caused by changes in serotonin activity, however it is unclear how Cyproheptadine exerts a beneficial effect on this condition.
Mechanism of actionCyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite.
Related Articles
AbsorptionWell absorbed after oral administration.
Volume of distributionNot Available
Protein binding96 to 99%
Metabolism

Hepatic (cytochrome P-450 system) and some renal.

Route of eliminationAfter a single 4 mg oral dose of14C-labelled cyproheptadine HCl in normal subjects, given as tablets 2% to 20% of the radioactivity was excreted in the stools. At least 40% of the administered radioactivity was excreted in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.986
Caco-2 permeable+0.8038
P-glycoprotein substrateSubstrate0.8598
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.5315
Renal organic cation transporterInhibitor0.8303
CYP450 2C9 substrateNon-substrate0.8127
CYP450 2D6 substrateNon-substrate0.6719
CYP450 3A4 substrateSubstrate0.6092
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9082
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5433
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9511
BiodegradationNot ready biodegradable0.8349
Rat acute toxicity2.9576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5429
hERG inhibition (predictor II)Inhibitor0.7423
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
Syruporal2 mg/5mL
Tabletoral4 mg
Tabletoral4 mg/1
Syruporal0.4 mg
Syruporal2 mg
Prices
Unit descriptionCostUnit
Cyproheptadine hcl powder7.34USD g
Cyproheptadine HCl 4 mg tablet0.47USD tablet
Cyproheptadine 4 mg tablet0.43USD tablet
Cyproheptadine HCl 2 mg/5ml Syrup0.16USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point112.3-113-3Engelhardt, E.L.; U S . Patent 3,014,911; December 26, 1961; assigned to Merck & Co., Inc.
water solubilitySolubleNot Available
logP4.69SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP5.02ALOGPS
logP4.38ChemAxon
logS-4.3ALOGPS
pKa (Strongest Basic)8.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity105.17 m3·mol-1ChemAxon
Polarizability34.17 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00kr-2290000000-a17c27a9f171b058f2c3View in MoNA
References
Synthesis Reference

Engelhardt, E.L.; U S . Patent 3,014,911; December 26, 1961; assigned to Merck & Co., Inc.

General References
  1. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
External Links
ATC CodesR06AX02
AHFS Codes
  • 04:04.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.3 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cyproheptadine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Cyproheptadine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Cyproheptadine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the anticholinergic activities of Cyproheptadine.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Cyproheptadine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Cyproheptadine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Cyproheptadine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyproheptadine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Cyproheptadine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyproheptadine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cyproheptadine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyproheptadine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Cyproheptadine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyproheptadine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cyproheptadine.
AmoxapineThe therapeutic efficacy of Amoxapine can be decreased when used in combination with Cyproheptadine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyproheptadine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Cyproheptadine.
AmphetamineAmphetamine may decrease the sedative activities of Cyproheptadine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyproheptadine.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Cyproheptadine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cyproheptadine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Cyproheptadine.
AzelastineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cyproheptadine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Cyproheptadine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Cyproheptadine.
BenmoxinBenmoxin may increase the anticholinergic activities of Cyproheptadine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Cyproheptadine.
BenzphetamineBenzphetamine may decrease the sedative activities of Cyproheptadine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Cyproheptadine.
Benzylpenicilloyl PolylysineCyproheptadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cyproheptadine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
BrimonidineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cyproheptadine.
BrompheniramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Cyproheptadine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyproheptadine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyproheptadine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyproheptadine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyproheptadine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Cyproheptadine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Cyproheptadine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Cyproheptadine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Cyproheptadine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyproheptadine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cyproheptadine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Cyproheptadine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyproheptadine.
CaroxazoneCaroxazone may increase the anticholinergic activities of Cyproheptadine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cyproheptadine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Cyproheptadine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyproheptadine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Cyproheptadine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cyproheptadine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Cyproheptadine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyproheptadine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyproheptadine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyproheptadine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyproheptadine.
CitalopramThe therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cyproheptadine.
ClidiniumThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Cyproheptadine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Cyproheptadine.
ClomipramineThe therapeutic efficacy of Clomipramine can be decreased when used in combination with Cyproheptadine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Cyproheptadine.
ClonazepamThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyproheptadine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cyproheptadine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cyproheptadine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyproheptadine.
CyclizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cyproheptadine.
DapoxetineThe therapeutic efficacy of Dapoxetine can be decreased when used in combination with Cyproheptadine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Cyproheptadine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyproheptadine.
DesipramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Cyproheptadine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cyproheptadine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Cyproheptadine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyproheptadine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyproheptadine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Cyproheptadine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyproheptadine.
DifenoxinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyproheptadine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyproheptadine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyproheptadine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cyproheptadine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyproheptadine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Cyproheptadine.
DoxepinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DoxylamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyproheptadine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Cyproheptadine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Cyproheptadine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cyproheptadine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Cyproheptadine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Cyproheptadine.
EfavirenzThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cyproheptadine.
EntacaponeThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Entacapone.
EscitalopramThe therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Cyproheptadine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyproheptadine.
EthanolCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Cyproheptadine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cyproheptadine.
EthosuximideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Cyproheptadine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Cyproheptadine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyproheptadine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Cyproheptadine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Cyproheptadine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Cyproheptadine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyproheptadine.
EtoperidoneThe therapeutic efficacy of Etoperidone can be decreased when used in combination with Cyproheptadine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyproheptadine.
EzogabineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Cyproheptadine.
FenfluramineThe therapeutic efficacy of Fenfluramine can be decreased when used in combination with Cyproheptadine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyproheptadine.
FexofenadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Cyproheptadine.
FlunarizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Cyproheptadine.
FluoxetineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cyproheptadine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyproheptadine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyproheptadine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyproheptadine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Cyproheptadine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fluticasone Propionate.
FluvoxamineThe therapeutic efficacy of Fluvoxamine can be decreased when used in combination with Cyproheptadine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyproheptadine.
FosphenytoinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Cyproheptadine.
FurazolidoneFurazolidone may increase the anticholinergic activities of Cyproheptadine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cyproheptadine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Cyproheptadine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Cyproheptadine.
GuanfacineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Cyproheptadine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyproheptadine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Cyproheptadine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Cyproheptadine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cyproheptadine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyproheptadine.
HydracarbazineHydracarbazine may increase the anticholinergic activities of Cyproheptadine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyproheptadine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyproheptadine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Cyproheptadine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
HydroxyzineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Imipramine.
IndalpineThe therapeutic efficacy of Indalpine can be decreased when used in combination with Cyproheptadine.
IproclozideIproclozide may increase the anticholinergic activities of Cyproheptadine.
IproniazidIproniazid may increase the anticholinergic activities of Cyproheptadine.
IsocarboxazidIsocarboxazid may increase the anticholinergic activities of Cyproheptadine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyproheptadine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyproheptadine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyproheptadine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyproheptadine.
LamotrigineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Cyproheptadine.
LevocabastineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyproheptadine.
LevomilnacipranThe therapeutic efficacy of Levomilnacipran can be decreased when used in combination with Cyproheptadine.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyproheptadine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cyproheptadine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Cyproheptadine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Cyproheptadine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Cyproheptadine.
LoratadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyproheptadine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyproheptadine.
Lu AA21004The therapeutic efficacy of Lu AA21004 can be decreased when used in combination with Cyproheptadine.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Cyproheptadine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Maprotiline.
MebanazineMebanazine may increase the anticholinergic activities of Cyproheptadine.
MeclizineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Cyproheptadine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Cyproheptadine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Cyproheptadine.
MephentermineMephentermine may decrease the sedative activities of Cyproheptadine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyproheptadine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyproheptadine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Cyproheptadine.
MetaxaloneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyproheptadine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cyproheptadine.
MethamphetamineMethamphetamine may decrease the sedative activities of Cyproheptadine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cyproheptadine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Cyproheptadine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyproheptadine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyproheptadine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Cyproheptadine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Cyproheptadine.
MethsuximideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Methsuximide.
Methylene blueMethylene blue may increase the anticholinergic activities of Cyproheptadine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyproheptadine.
MetyrosineCyproheptadine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyproheptadine.
MilnacipranThe therapeutic efficacy of Milnacipran can be decreased when used in combination with Cyproheptadine.
MinaprineMinaprine may increase the anticholinergic activities of Cyproheptadine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
MirtazapineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyproheptadine.
MoclobemideMoclobemide may increase the anticholinergic activities of Cyproheptadine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Cyproheptadine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyproheptadine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.
NabiloneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyproheptadine.
NialamideNialamide may increase the anticholinergic activities of Cyproheptadine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cyproheptadine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Cyproheptadine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Cyproheptadine.
NortriptylineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Nortriptyline.
OctamoxinOctamoxin may increase the anticholinergic activities of Cyproheptadine.
OlanzapineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with Cyproheptadine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine.
OlopatadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cyproheptadine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Cyproheptadine.
OrphenadrineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cyproheptadine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Cyproheptadine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyproheptadine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyproheptadine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cyproheptadine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyproheptadine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyproheptadine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cyproheptadine.
ParaldehydeCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Cyproheptadine.
PargylinePargyline may increase the anticholinergic activities of Cyproheptadine.
ParoxetineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyproheptadine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyproheptadine.
PerampanelThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Cyproheptadine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyproheptadine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyproheptadine.
PhenelzinePhenelzine may increase the anticholinergic activities of Cyproheptadine.
PheniprazinePheniprazine may increase the anticholinergic activities of Cyproheptadine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cyproheptadine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Cyproheptadine.
PhenoxypropazinePhenoxypropazine may increase the anticholinergic activities of Cyproheptadine.
PhenterminePhentermine may decrease the sedative activities of Cyproheptadine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Cyproheptadine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Cyproheptadine.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cyproheptadine.
PipotiazineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pipotiazine.
PirlindolePirlindole may increase the anticholinergic activities of Cyproheptadine.
PivhydrazinePivhydrazine may increase the anticholinergic activities of Cyproheptadine.
PizotifenThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pomalidomide.
PramipexoleCyproheptadine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Cyproheptadine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyproheptadine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyproheptadine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Cyproheptadine.
PrimidoneThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cyproheptadine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyproheptadine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyproheptadine.
PromethazineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cyproheptadine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyproheptadine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Cyproheptadine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyproheptadine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Cyproheptadine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyproheptadine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyproheptadine.
RamelteonThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ramelteon.
RasagilineRasagiline may increase the anticholinergic activities of Cyproheptadine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyproheptadine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cyproheptadine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyproheptadine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyproheptadine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Cyproheptadine.
RopiniroleCyproheptadine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyproheptadine.
RotigotineCyproheptadine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyproheptadine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Cyproheptadine.
SafrazineSafrazine may increase the anticholinergic activities of Cyproheptadine.
ScopolamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyproheptadine.
SelegilineSelegiline may increase the anticholinergic activities of Cyproheptadine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Cyproheptadine.
SertralineThe therapeutic efficacy of Sertraline can be decreased when used in combination with Cyproheptadine.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyproheptadine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Cyproheptadine.
StiripentolThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cyproheptadine.
SuvorexantThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyproheptadine.
TetrabenazineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Cyproheptadine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Cyproheptadine.
ThalidomideCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cyproheptadine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyproheptadine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Cyproheptadine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cyproheptadine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cyproheptadine.
TiagabineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Cyproheptadine.
TizanidineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cyproheptadine.
ToloxatoneToloxatone may increase the anticholinergic activities of Cyproheptadine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Cyproheptadine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyproheptadine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the anticholinergic activities of Cyproheptadine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the anticholinergic activities of Cyproheptadine.
TranylcypromineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tranylcypromine.
TrazodoneThe therapeutic efficacy of Trazodone can be decreased when used in combination with Cyproheptadine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyproheptadine.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyproheptadine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyproheptadine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyproheptadine.
TrimipramineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Cyproheptadine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cyproheptadine.
VigabatrinThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Vigabatrin.
VilazodoneThe therapeutic efficacy of Vilazodone can be decreased when used in combination with Cyproheptadine.
VortioxetineThe therapeutic efficacy of Vortioxetine can be decreased when used in combination with Cyproheptadine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyproheptadine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Cyproheptadine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyproheptadine.
ZiconotideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ziconotide.
ZimelidineThe therapeutic efficacy of Zimelidine can be decreased when used in combination with Cyproheptadine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyproheptadine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Cyproheptadine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cyproheptadine.
ZonisamideThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Cyproheptadine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Cyproheptadine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyproheptadine.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Rashid M, Nakazawa M, Nagatomo T: Effects of sarpogrelate, a novel 5-HT2 antagonist, on 5-HT-induced endothelium-dependent relaxations in porcine coronary artery. Jpn J Pharmacol. 2002 Aug;89(4):405-12. [PubMed:12233819 ]
  2. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911 ]
  3. Callaway CW, Rempel N, Peng RY, Geyer MA: Serotonin 5-HT1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology. 1992 Sep;7(2):113-27. [PubMed:1358088 ]
  4. Hoenicke EM, Vanecek SA, Woods JH: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther. 1992 Oct;263(1):276-84. [PubMed:1403790 ]
  5. Calka O, Metin A, Dulger H, Erkoc R: Effect of cyproheptadine on serum leptin levels. Adv Ther. 2005 Sep-Oct;22(5):424-8. [PubMed:16418149 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Eltze M, Lambrecht G, Mutschler E: Cyproheptadine displays high affinity for muscarinic receptors but does not discriminate between receptor subtypes. Eur J Pharmacol. 1989 Dec 7;173(2-3):219-22. [PubMed:2625138 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Eltze M, Lambrecht G, Mutschler E: Cyproheptadine displays high affinity for muscarinic receptors but does not discriminate between receptor subtypes. Eur J Pharmacol. 1989 Dec 7;173(2-3):219-22. [PubMed:2625138 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Eltze M, Lambrecht G, Mutschler E: Cyproheptadine displays high affinity for muscarinic receptors but does not discriminate between receptor subtypes. Eur J Pharmacol. 1989 Dec 7;173(2-3):219-22. [PubMed:2625138 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. [PubMed:9616184 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23